Abstract

Objective: Ester conjugates of HIV protease inhibitor, lopinavir (LP) with various amino acids were synthesized to improve its physicochemical and pharmacokinetic profile and consequently therapeutic potential.
 Materials and Methods: Conjugates of LP with amino acids; glycine, alanine, valine, and serine were prepared by dicyclohexylcarbodiimide coupling method. The synthesized compounds were characterized by nuclear magnetic resonance, mass, and Fourier-transform infrared spectroscopy and evaluated for their solubility, partition coefficient, hydrolytic stability, cytotoxicity, and permeability through Caco-2 cells.
 Results: Aqueous solubility studies indicated significantly better solubility profiles of all conjugates as compared to LP. With respect to hydrolysis, all the conjugates displayed higher stability under acidic conditions while undergo hydrolysis with rise in pH. Conjugates did not exhibit cytotoxicity for concentration as high as 100 μg/ml, which indicates promising therapeutic potential. Absorptive diffusion of drug across Caco-2 cell monolayers was improved by amino acid conjugation.
 Conclusion: Amino acid ester conjugates of LP not only showed better solubility but also significantly higher permeability than LP. Thus, direct conjugation of L-amino acids is a viable approach to improve oral absorption and thereby oral bioavailability of protease inhibitors.

Highlights

  • Several strategies have been adopted for the effective treatment of HIV/AIDS since 1984

  • Chemistry The LP ester conjugates were synthesized by the dicyclohexylcarbodiimide coupling method

  • Glycine, alanine, valine, and serine were identified as carriers for the synthesis of LP ester conjugates

Read more

Summary

Introduction

Several strategies have been adopted for the effective treatment of HIV/AIDS since 1984. HIV PIs represent an important class of antiHIV drugs in highly active antiretroviral therapy regimen. Lopinavir (LP) is potent and one of the frequently administered PIs in the treatment of the HIV [1]. LP is classified as a BCS II drug (high permeability/low solubility). It has very poor bioavailability when administered orally which is due to low water solubility, limited intestinal uptake due to P-glycoprotein efflux and high first-pass metabolism by cytochrome P450 [2,3,4,5].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call